BUZZ-Bristol Myers rises after FDA accepts application for combo drug for colorectal cancer

Shares of drugmaker Bristol Myers Squibb BMY.N up 3.2% at $57.61

Co says the U.S. FDA has accepted for review its marketing application seeking approval of the combination of BMY's Opdivo plus Yervoy as a potential first-line treatment option for patients with types of colorectal cancer

The FDA is set to make a decision by June 23

Opdivo plus Yervoy is already approved to treat cancers of the skin, lung, kidney, colon and esophagus

BMY has rose ~10% in the last 12 months